Señales en vivo de AFMD | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 may 2024 @ 16:00):

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe...

Stats
Volumen de hoy	18 645.00
Volumen promedio	96 331.00
Capitalización de mercado	79.72M
EPS	€0 ( 2024-03-28 )
Próxima fecha de ganancias	( €-1.860 ) 2024-05-28
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.690
ATR14	€0.0390 (0.74%)

Volumen Correlación

Largo: 0.16 (neutral)

Corto: -0.38 (neutral)

Signal:(56.522) Neutral

Affimed NV Correlación

10 Correlaciones Más Positivas
ADAP	0.95
TNON	0.947
ONCR	0.941
EDTK	0.938
SOPA	0.938
AIHS	0.937
SEED	0.936
GRNV	0.934
ONCS	0.934
EDAP	0.933

10 Correlaciones Más Negativas
ADBE	-0.958
FTIV	-0.953
PTMN	-0.951
WDAY	-0.946
MURFU	-0.946
NEWT	-0.944
ATLCP	-0.943
TATT	-0.942
AMWD	-0.942
RMRM	-0.942

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Affimed NV Correlación - Moneda/Commodity

-0.31
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.17
( neutral )

0.20
( neutral )

0.33
( neutral )

Affimed NV Finanzas

Annual	2023
Ingresos:	€8.28M
Beneficio Bruto:	€8.28M (100.00 %)
EPS:	€-7.09

FY	2023
Ingresos:	€8.28M
Beneficio Bruto:	€8.28M (100.00 %)
EPS:	€-7.09

FY	2022
Ingresos:	€41.35M
Beneficio Bruto:	€41.35M (100.00 %)
EPS:	€-0.600

FY	2021
Ingresos:	€40.37M
Beneficio Bruto:	€0.00 (0.00 %)
EPS:	€-0.480

Financial Reports:

No articles found.

Affimed NV

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.